Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | BCR | P11274 | 1/20 | 0.43 |
| ▸ | CFD | P00746 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 4/20 | 0.41 |
| ▸ | JAK2 | O60674 | 3/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3603519 | 0.92 | SYK (0.49) | ABL1EGFRSRCBCRSYK | |
| SCHEMBL14140367 | 0.89 | ABL1 (0.48) | ABL1EGFRSRCBCRSYK | |
| SCHEMBL3605169 | 0.88 | CDK2 (0.51) | ABL1BCRJAK2CDK1CDK2 | |
| SCHEMBL3603517 | 0.86 | ABL1 (0.41) | ABL1EGFRSRCBCRSYK | |
| SCHEMBL3609681 | 0.85 | CDK2 (0.51) | ABL1EGFRSRCBCRCDK1 | |
| SCHEMBL3604092 | 0.83 | CDK1 (0.54) | EGFRSYKJAK2CDK1CDK2 | |
| SCHEMBL3606836 | 0.81 | SYK (0.47) | ABL1BCRSYKCDK1CDK2 | |
| SCHEMBL3610719 | 0.81 | CAMK2D (0.54) | ABL1BCRCDK1CDK2MTOR | |
| SCHEMBL3602605 | 0.78 | CDK2 (0.50) | ABL1BCRJAK2CDK1CDK2 | |
| SCHEMBL3608990 | 0.78 | MAPT (0.52) | ABL1EGFRSRCBCRJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048597-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | ABL1 3215/4885EGFR 4114/4885SRC 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.